MacrogenicsFRA:M55 -1.01%52 PB Ratio is 13.68 as of Jul. 12, 2026, which is 390% above its 10-year median of 2.79. GuruFocus rates FRA:M55 with a GF Score™ of 52/100 and a GF Value™ of €3.36 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,231 Biotechnology companies, Macrogenics ranks worse than 89.44% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-12), Macrogenics's share price is €3.94. Macrogenics's Book Value per Share for the quarter that ended in Mar. 2026 was €0.29. Hence, Macrogenics's PB Ratio of today is 13.68.
The historical rank and industry rank for Macrogenics's PB Ratio or its related term are showing as below:
FRA:M55'
s PB Ratio Range Over the Past 10 Years
Min: 0.68 Med: 2.79 Max: 14.4
Current: 12.96
During the past 13 years, Macrogenics's highest PB Ratio was 14.40. The lowest was 0.68. And the median was 2.79.
FRA:M55's PB Ratio is ranked worse than 89.44% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:M55: 12.96
During the past 12 months, Macrogenics's average Book Value Per Share Growth Rate was -73.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -27.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -18.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Macrogenics was 35.00% per year. The lowest was -27.50% per year. And the median was -14.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Macrogenics PB Ratio Related Terms
Macrogenics PB Ratio Historical Data
* Premium members only.
The historical data trend for Macrogenics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Macrogenics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Macrogenics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Macrogenics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Macrogenics (FRA:M55) has a PB Ratio of 13.68 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Macrogenics and its competitors. This is 390% above median its historical median of 2.79. Over the past decade, Macrogenics' PB Ratio has ranged from 0.68 to 14.40. According to the industry distribution chart, Macrogenics ranks #1101 out of 1231 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Macrogenics' PB Ratio too high?
Macrogenics' current PB Ratio of 13.68 is 390% above median its 10-year median of 2.79. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 14.40. The Biotechnology industry median PB Ratio is 2.93. Macrogenics' value of 13.68 is 366.9% above this industry median. Based on the distribution chart, Macrogenics ranks #1101 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Macrogenics has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' PB Ratio compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #1101 out of 1231 companies for PB Ratio. This places Macrogenics in the lower half of its industry. The industry median PB Ratio is 2.93. Macrogenics' value of 13.68 is 366.9% above this benchmark. Historically, Macrogenics' own PB Ratio has ranged from 0.68 to 14.40 over the past decade. While the company's 10-year median is 2.79 vs. the industry median of 2.93, Macrogenics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Macrogenics's current PB Ratio of 13.68 is 366.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Macrogenics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current PB Ratio is 13.68, which is 390% above median its own 10-year median of 2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.36, compared to a current price of €3.94 — trading 17.3% above its estimated fair value. The current PB Ratio is 13.68, which is 390% above median its 10-year median of 2.79 and 366.9% above the Biotechnology industry median of 2.93. Macrogenics' overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current PB Ratio is 13.68 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €3.94 is trading 17.3% above its estimated GF Value™ of €3.36.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for FRA:M55:
PB Ratio: 13.68 (390% above median its 10-year median of 2.79)
GF Value™: €3.36 vs. price of €3.94 (17.3% above fair value)
Industry Position: 366.9% above the Biotechnology median (#1101 of 1231)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
52GF Score
Get the complete analysis for FRA:M55
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
